Madrigal Pharmaceuticals, Inc. (MDGL) shareholders
Close on Nov 16, 2026Market cap $9.80BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (9.99%), Julian C. Baker (9.99%) and 1 more | 2,330,144 | 9.99% | 13D (active) amendment | Nov 6, 2026 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (9.90%) | 2,288,888 | 9.90% | 13G (passive) amendment | Dec 31, 2023 |
| Julian C. Baker Joint filing with Baker Bros. Advisors LP (9.99%), Baker Bros. Advisors (GP) LLC (9.99%) and 1 more | 2,070,544 | 9.99% | 13D (active) amendment | Mar 21, 2024 |
| Janus Henderson Group PLC | 2,018,647 | 8.80% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong, M.D Joint filing with RTW Investments, LP (9.20%) | 1,993,687 | 9.20% | 13G (passive) | Sep 30, 2024 |
| Rebecca Taub, M.D. | 1,814,831 | 7.80% | 13D (active) amendment | Dec 10, 2025 |
| Paul A Friedman, M.D. | 1,814,831 | 7.80% | 13D (active) amendment | Dec 10, 2025 |
| Paulson & Co. Inc. | 1,392,188 | 6.10% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MDGL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 2,143,131 | 9.28% | $1.15B | +1,430 | 5.77% |
| Rtw Investments, LP | 1,993,687 | 8.63% | $1.07B | – | 9.14% |
| Jupiter Topco LLC | 1,936,099 | 8.38% | $1.04B | New | 0.42% |
| Avoro Capital Advisors LLC | 1,833,333 | 7.94% | $984.41M | +15,152 | 8.84% |
| Paulson & Co. Inc. | 1,340,020 | 5.80% | $719.52M | −52,168 | 27.94% |
| BlackRock, Inc. | 1,200,770 | 5.20% | $644.75M | −359,195 | 0.01% |
| Vanguard Capital Management LLC | 835,668 | 3.62% | $448.71M | +8,524 | 0.01% |
| Wellington Management Group Llp | 825,714 | 3.57% | $443.37M | +130,756 | 0.08% |
| Vanguard Portfolio Management LLC | 781,731 | 3.38% | $419.75M | −59,414 | 0.02% |
| State Street Corp | 527,057 | 2.28% | $283.00M | −82,468 | 0.01% |
| Citadel Advisors LLC | 507,233 | 2.20% | $272.36M | +53,390 | 0.03% |
| UBS Group AG | 401,708 | 1.74% | $215.70M | +283,929 | 0.03% |
| Geode Capital Management, LLC | 374,880 | 1.62% | $201.34M | −80,990 | 0.01% |
| FMR LLC | 356,201 | 1.54% | $191.26M | −155,527 | 0.01% |
| William Blair Investment Management, LLC | 324,123 | 1.40% | $174.04M | −16,396 | 0.52% |
| Invesco Ltd. | 301,435 | 1.30% | $161.86M | −28,084 | 0.01% |
| Armistice Capital, LLC | 288,000 | 1.25% | $154.64M | +23,417 | 1.89% |
| Lord, Abbett & Co. LLC | 281,500 | 1.22% | $151.15M | +38,774 | 0.43% |
| Assenagon Asset Management S.A. | 248,428 | 1.08% | $133.39M | +232,395 | 0.08% |
| Goldman Sachs Group Inc | 246,280 | 1.07% | $132.24M | −31,091 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 413 | 24M | 100.0% | 79 / 144 | 131 / 41 | 5M | 3M |
| Q1 2026 | 380 | 24M | 100.0% | 63 / 130 | 130 / 64 | 4M | 2M |
| Q4 2025 | 387 | 24M | 100.0% | 85 / 137 | 113 / 41 | 2M | 2M |
| Q3 2025 | 352 | 23M | 100.0% | 87 / 107 | 107 / 37 | 3M | 3M |
| Q2 2025 | 305 | 24M | 100.0% | 38 / 107 | 110 / 51 | 2M | 2M |
| Q1 2025 | 321 | 24M | 100.0% | 73 / 110 | 91 / 32 | 2M | 1M |
| Q4 2024 | 283 | 23M | 99.4% | 67 / 95 | 77 / 37 | 2M | 2M |
| Q3 2024 | 257 | 23M | 98.4% | 45 / 86 | 83 / 43 | 3M | 2M |
| Q2 2024 | 257 | 23M | 99.2% | 49 / 111 | 64 / 55 | 4M | 2M |
| Q1 2024 | 266 | 22M | 94.5% | 74 / 87 | 78 / 33 | 4M | 3M |
| Q4 2023 | 226 | 20M | 86.5% | 56 / 92 | 57 / 32 | 5M | 2M |
| Q3 2023 | 205 | 17M | 75.2% | 37 / 89 | 54 / 38 | 4M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
372 funds held MDGL in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MDGL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 584,997 | 2.53% | $314.11M | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Fund | 563,117 | 2.44% | $263.16M | 0.69% | Jul 31, 2026 |
| Vanguard Small-Cap Index Fund | 423,142 | 1.83% | $227.21M | 0.12% | Jun 30, 2026 |
| Janus Henderson Forty Fund | 338,602 | 1.47% | $181.81M | 0.76% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 243,683 | 1.05% | $130.85M | 0.28% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund | 233,269 | 1.01% | $125.25M | 0.56% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 216,882 | 0.94% | $116.45M | 0.12% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 211,251 | 0.91% | $113.43M | 1.06% | Jun 30, 2026 |
| Vanguard Explorer Fund | 190,140 | 0.82% | $88.86M | 0.40% | Jul 31, 2026 |
| Janus Henderson Contrarian Fund | 168,259 | 0.73% | $90.35M | 1.65% | Jun 30, 2026 |
| iShares Biotechnology ETF | 153,736 | 0.67% | $82.55M | 0.91% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 145,364 | 0.63% | $78.05M | 1.34% | Jun 30, 2026 |
| Lord Abbett Growth Leaders Fund | 140,436 | 0.61% | $65.63M | 0.88% | Jul 31, 2026 |
| Invesco Discovery Fund | 119,197 | 0.52% | $59.27M | 0.76% | May 31, 2026 |
| iShares Russell Mid-Cap Growth ETF | 105,779 | 0.46% | $56.80M | 0.26% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William John Sibold | President and CEO, Director | 202,801 | 0.88% | Sep 11, 2026 |
| Shannon T. Kelley | General Counsel | 10,397 | 0.05% | Nov 6, 2026 |
| David Soergel | Chief Medical Officer | 10,033 | 0.04% | Jun 1, 2026 |
| Carole Huntsman | Chief Commercial Officer | 12,692 | 0.05% | Mar 6, 2026 |
| Mardi Dier | EVP and CFO | 12,850 | 0.06% | Mar 6, 2026 |
| Rita Thakkar | Chief Accounting Officer | 2,398 | 0.01% | Jan 20, 2026 |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | 10,918 | 0.05% | Mar 7, 2025 |
| 667, L.P. | Director | 1,669,016 | 7.22% | Nov 6, 2026 |
| Bros. Advisors Lp Baker | Director | 2,040,682 | 8.83% | Nov 6, 2026 |
| Julian Baker | Director | 1,612,339 | 6.98% | Nov 6, 2026 |
| Felix Baker | Director | 1,843,469 | 7.98% | Nov 6, 2026 |
| Brothers Life Sciences LP Baker | Director | 1,948,876 | 8.44% | Nov 6, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 1,947,968 | 8.43% | Nov 6, 2026 |
| John C. Reed | Director | 647 | 0.00% | Aug 18, 2026 |
| Daniel J. Brennan | Director | 1,371 | 0.01% | Jun 18, 2026 |
| Rebecca Taub | Director | 1,108,207 | 4.80% | Jun 18, 2026 |
| Jacqualyn A. Fouse | Director | 1,551 | 0.01% | Jun 18, 2026 |
| Richard S. Levy | Director | 22,469 | 0.10% | Jun 18, 2026 |
| James M. Daly | Director | 3,081 | 0.01% | Jun 18, 2026 |
| Paul A. Friedman | Director | 855,884 | 3.70% | Jan 13, 2026 |
| Kenneth Bate | Director | 8,896 | 0.04% | Nov 7, 2025 |
| Fred B. Craves | Director | 390,028 | 1.69% | Mar 14, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shannon T. Kelley General Counsel | Nov 6, 2026 | Sale(10b5-1 plan) | −1,077 | $400.00 | $430.80K | 10,397 |
| Bros. Advisors Lp Baker Director | Nov 6, 2026 | Buy | +2,000 | $396.61 | $793.22K | 2,040,682 |
| Bros. Advisors Lp Baker Director | Nov 6, 2026 | Buy | +13,740 | $388.29 | $5.34M | 2,038,682 |
| Bros. Advisors Lp Baker Director | Nov 6, 2026 | Buy | +60,400 | $383.01 | $23.13M | 2,024,942 |
| Bros. Advisors Lp Baker Director | Nov 4, 2026 | Buy | +10,080 | $368.11 | $3.71M | 1,964,542 |
| Bros. Advisors Lp Baker Director | Nov 4, 2026 | Buy | +5,586 | $366.99 | $2.05M | 1,954,462 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −106 | $534.06 | $56.61K | 202,801 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −120 | $546.38 | $65.57K | 197,746 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −761 | $544.83 | $414.62K | 197,866 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,539 | $544.02 | $837.25K | 198,627 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,202 | $542.60 | $652.21K | 200,166 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −368 | $541.64 | $199.32K | 201,368 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −687 | $540.59 | $371.39K | 201,736 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −160 | $537.62 | $86.02K | 202,423 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −218 | $535.94 | $116.83K | 202,583 |
| William John Sibold President and CEO, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −60 | $533.09 | $31.99K | 202,907 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −362 | $541.65 | $196.08K | 203,127 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −505 | $540.19 | $272.80K | 203,489 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −215 | $539.03 | $115.89K | 203,994 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −520 | $538.30 | $279.92K | 204,209 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −640 | $537.17 | $343.79K | 204,729 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −1,040 | $536.11 | $557.55K | 205,369 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −644 | $535.27 | $344.71K | 206,409 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −396 | $534.20 | $211.54K | 207,053 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −512 | $533.09 | $272.94K | 207,449 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −368 | $531.99 | $195.77K | 207,961 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −522 | $530.23 | $276.78K | 208,329 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −347 | $529.27 | $183.66K | 208,851 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −131 | $527.88 | $69.15K | 209,198 |
| William John Sibold President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −160 | $542.55 | $86.81K | 202,967 |
| Shannon T. Kelley General Counsel | Aug 17, 2026 | Sale | −664 | $514.97 | $341.94K | 11,474 |
| John C. Reed Director | Aug 15, 2026 | Award | +647 | – | – | 647 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −140 | $542.75 | $75.99K | 211,689 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −110 | $543.79 | $59.82K | 211,579 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −275 | $545.71 | $150.07K | 210,759 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −269 | $547.08 | $147.16K | 210,490 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −680 | $547.70 | $372.44K | 209,810 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −47 | $548.87 | $25.80K | 209,763 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −153 | $550.01 | $84.15K | 209,610 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −1 | $550.72 | $551 | 209,609 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −280 | $555.05 | $155.41K | 209,329 |
| William John Sibold President and CEO, Director | Jul 20, 2026 | Sale | −545 | $544.71 | $296.87K | 211,034 |
| William John Sibold President and CEO, Director | Jul 17, 2026 | Option exercise | +50,000 | – | – | 211,829 |
| Daniel J. Brennan Director | Jun 17, 2026 | Award | +404 | – | – | 1,371 |
| James M. Daly Director | Jun 17, 2026 | Award | +454 | – | – | 3,081 |
| Richard S. Levy Director | Jun 17, 2026 | Award | +454 | – | – | 22,469 |
| Jacqualyn A. Fouse Director | Jun 17, 2026 | Award | +454 | – | – | 1,551 |
| Brothers Life Sciences LP Baker Director | Jun 17, 2026 | Award | +908 | – | – | 1,948,876 |
| Brothers Life Sciences LP Baker Director | Jun 17, 2026 | Award | +908 | – | – | 203,721 |
| Rebecca Taub Director | Jun 17, 2026 | Award | +454 | – | – | 452,667 |
| David Soergel Chief Medical Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −1,042 | $495.74 | $516.56K | 10,033 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −320 | $508.24 | $162.64K | 27,337 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −40 | $506.68 | $20.27K | 27,657 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −151 | $510.36 | $77.06K | 27,186 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −610 | $511.40 | $311.95K | 26,576 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −439 | $512.50 | $224.99K | 26,137 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −40 | $512.97 | $20.52K | 26,097 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −343 | $514.67 | $176.53K | 25,754 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −657 | $515.92 | $338.96K | 25,097 |
| Richard S. Levy Director | May 22, 2026 | Sale(10b5-1 plan) | −723 | $516.87 | $373.70K | 24,374 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Madrigal Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,700 shares on Oct 7, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shannon T. Kelley Officer | Nov 6, 2026 | 1,077 | $430.91K | Nov 6, 2026 | Restricted Stock Units |
| Paul A. Friedman Director | Sep 28, 2026 | 50,000 | $25.83M | Sep 28, 2026 | Exercise of Stock Options |
| William John Sibold Director, Officer | Sep 11, 2026 | 5,221 | $2.78M | Sep 11, 2026 | Restricted Stock Units |
| William John Sibold Officer and Director | Sep 9, 2026 | 6,362 | $3.40M | Sep 9, 2026 | Restricted Stock Unit Grant |
| Shannon T. Kelley Officer | Aug 20, 2026 | 664 | $337.02K | Aug 17, 2026 | Restricted Stock Unit Grant |
| William John Sibold Officer and Director | Jul 20, 2026 | 2,500 | $1.38M | Jul 20, 2026 | Performance Restricted Stock Unit Grant |
| David Soergel Officer | Jun 1, 2026 | 1,042 | $518.16K | Jun 1, 2026 | Restricted Stock Units |
| Richard S. Levy Director | May 22, 2026 | 5,682 | $2.92M | May 22, 2026 | Previously Exercised Stock Options |
| David Soergel Officer | May 18, 2026 | 844 | $441.99K | May 18, 2026 | Restricted Stock Unit Grant |
| Shannon T. Kelley Officer | Mar 6, 2026 | 360 | $158.16K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Carole Huntsman Officer | Mar 6, 2026 | 419 | $184.08K | Mar 6, 2026 | Restricted Stock Unit Grant |
| William John Sibold Officer and Director | Mar 6, 2026 | 1,663 | $730.62K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Mardi Dier Officer | Mar 6, 2026 | 646 | $283.81K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Rebecca Taub Director | Mar 6, 2026 | 491 | $215.72K | Mar 6, 2026 | Restricted Stock Unit Grant |
| Mardi Dier Officer | Mar 6, 2026 | 1,336 | $586.96K | Mar 6, 2026 | Restricted Stock Units |
See a number that looks wrong?